DM4-SMCC |CAS 1228105-52-9|DC Chemicals

Cas No.:	1228105-52-9
Chemical Name:	DM4-SMCC
Synonyms:	DM4-SMCC;(2,5-Dioxopyrrolidin-1-yl) 4-[[3-[5-[[(2S)-1-[[(1S,2R,3S,5S,6S,16Z,18Z,20R,21S)-11-chloro-21-hydroxy;AKOS040743235;1228105-52-9
SMILES:	ClC1C(=CC2CC(C)=CC=C[C@H]([C@]3(C[C@@H]([C@@H](C)[C@H]4[C@](C)([C@H](CC(N(C)C=1C=2)=O)OC([C@H](C)N(C)C(CCC(C)(C)SC1CC(N(C1=O)CC1CCC(C(=O)ON2C(CCC2=O)=O)CC1)=O)=O)=O)O4)OC(N3)=O)O)OC)OC \|c:7,9\|
Formula:	C₅₄H₇₂ClN₅O₁₆S
M.Wt:	1114.69139385223
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

MSDS

Cat. No.	Product name	Field of application
DC67529	DM4-SMCC	DM4-SMCC is an antibody-drug conjugate (ADC) payload that combines the potent antitubulin agent DM4 with a non-cleavable SMCC linker. This conjugate is designed to deliver cytotoxic effects specifically to tumor cells, leveraging DM4's ability to disrupt microtubule dynamics. The stable SMCC linker ensures controlled drug release, enhancing the ADC's antitumor activity while minimizing off-target toxicity.
DC66368	sulfo-SPDB-DM4	sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
DC80073	Azido-PEG4-EV-Cit-PAB-MMAE	Azido-PEG4-EV-Cit-PAB-MMAE is a precursor of antibody drug conjugate.
DC57082	MC-MMAE	Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a drug-linker conjugate for ADC.
DC39818	CL2-SN-38(DCA)	CL2-SN-38 is a cleavable linker-based antibody-drug conjugate (ADC) containing the topoisomerase I inhibitor SN-38 (Item No. 15632) and a maleimidocaproyl linker.1 CL2-SN-38 has been linked to tumor-selective human monoclonal antibodies, such as anti-CEACAM5 (hMN-14) to target SN-38 to tumor sites and improve its solubility. CL2-SN-38 linked to hMN-14 binds (Kd = 1.4 nM) and is cytotoxic to LoVo human colon adenocarcinoma cells (IC50 = 5.3 nM). CL2-SN-38 linked to hMN-14 increases survival in a colon carcinoma mouse model of lung metastasis.
DC75721	CL2A-SN38 (Govitecan)	CL2A-SN38 is a SN38 derivative with a peptide-linker which can easily react with antibody to form an antibody-drug conjugate (ADC). CL2A-SN-38 is composed of a potent a DNA Topoisomerase I inhibitor SN-38 and a linker CL2A to make antibody drug conjugate (ADC). CL2A-SN-38 provides significant and specific antitumor effects against a range of human solid tumor types. CL2A is a noncleavable complicated PEG8- and triazole-containing PABC-peptide-mc linker. CL2A is cleavable through pH sensitivity, giving rise to bystander effect, and binds the antibody at a cysteine residue via a disulfide bond. .
DC74470	SuO-Val-Cit-PAB-MMAE	A drug-linker conjugate for antibody-drug conjugate by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the cleavable peptide SuO-Val-Cit-PAB..
DC72532	Fmoc-VAP-MMAE	Fmoc-VAP-MMAE is a drug-linker conjugates for ADC. Fmoc-VAP-MMAE consists of an ADC linker and a tubulin inhibitor MMAE, with a protective Fmoc group.
DC72119	Deruxtecan analog 2	Deruxtecan analog 2 (example 9 P3) is a Deruxtecan analog. Deruxtecan analog 2 is a drug-linker conjugate composed of Camptothecin and a linker. Camptothecin (CPT) is a Topo I inhibitor with antineoplastic activity against colorectal, breast, lung and ovarian cancers. Deruxtecan analog 2 can be used for the preparation anti-FGFR2 ADC.
DC71950	Ac-Lys-Val-Cit-PABC-MMAE	Ac-Lys-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE.